Rahul Sarugaser Archives

Markets

RJ ups Profound Medical to strong buy

Raymond James upgraded Profound Medical (NASDAQ:PROF; TSX:PRN) to “strong buy” from “outperform” with a price target of $20.00, after pricing-in the TULSA-PRO system’s 2025 sales inflection. At mid-day on September 18...

September 18, 2023

Markets

Raymond James ups Eupraxia PT on new osteoarthritis data

Raymond James raised its price target for Eupraxia Pharmaceuticals (TSX:EPRX) to $17 (Canadian) from $11, maintaining a “strong buy” rating, after the company reported positive Phase 2b data with EP-104IAR for pain...

June 27, 2023

Markets

RJ ups Eupraxia to strong buy ahead of Phase 2 OA data

Raymond James upgraded Eupraxia Pharmaceuticals (TSX:EPRX) to “strong buy” from “outperform” and maintained its price target of $11 (Canadian). The stock was quoted at $6.99, up 15 cents at midday on May 18. Pointing to...

May 18, 2023

Markets

RJ highlights takeaways from KOL presentations on Profound’s TULSA-PRO

In a new report, Raymond James analyst, Rahul Sarugaser, Ph.D., outlined his five main takeaways from presentations from four key opinion leaders – Yale, UCLA, Mayo Clinic and WellSpan Health – about their clinical...

March 15, 2023

Markets

Raymond James, AGP up Profound Medical PTs as AMA to consider CPT approval

Raymond James raised its price target for Profound Medical (NASDAQ:PROF) to $17 from $15 and reiterated a “strong buy” rating after the company said its application for full CPT-1 reimbursement for TULSA-PRO has been...

March 8, 2023

Markets

Raymond James ups Quipt Home Medical PT after acquisition

Raymond James raised its price target for Quipt Home Medical (NASDAQ:QIPT; TSXV:QIPT) to $14 from $10, and reiterated its “outperform” rating after the company acquired Great Elm Healthcare for about $80-million. The...

January 4, 2023

Markets

Raymond James sees catalyst-rich two years ahead for Profound

Raymond James analyst, Rahul Sarugaser, Ph.D., outlined a series of potential catalysts for Profound Medical (NASDAQ:PROF; TSX:PRN), through 2023 and 2024 as it continues to commercialize its TULSA-PRO medical device to...

December 19, 2022

Markets

Raymond James starts POINT Biopharma at OP; PT $10

Raymond James initiated coverage of POINT Biopharma (NASDAQ:PNT) with an “outperform” rating and price target of $10 target. The stock closed at $6.61 on Dec. 13. POINT is a precision oncology company focused on the...

December 14, 2022

Developments

Raymond James sees high likelihood of CPT-1 reimbursement for Profound’s TULSA-PRO

Analyst Rahul Sarugaser, Ph.D., writes that there is a high likelihood that Profound Medical (NASDAQ:PROF) will receive a category-1 CPT code from the Centers for Medicare and Medical Services when it files an...

November 15, 2022

Markets

Raymond James ups Eupraxia PT to $9 (Canadian) on Phase 2 EoE trial

Raymond James raised its price target for Eupraxia Pharmaceuticals (TSXV:EPRX) to $9 (Canadian) from $7 and reiterated its “outperform” rating after the company initiated a Phase 2 clinical trial in eosinophilic...

October 31, 2022

Tag - Rahul Sarugaser

RJ ups Profound Medical to strong buy

Raymond James ups Eupraxia PT on new osteoarthritis data

RJ ups Eupraxia to strong buy ahead of Phase 2 OA data

RJ highlights takeaways from KOL presentations on Profound’s TULSA-PRO

Raymond James, AGP up Profound Medical PTs as AMA to consider CPT approval

Raymond James ups Quipt Home Medical PT after acquisition

Raymond James sees catalyst-rich two years ahead for Profound

Raymond James starts POINT Biopharma at OP; PT $10

Raymond James sees high likelihood of CPT-1 reimbursement for Profound’s TULSA-PRO

Raymond James ups Eupraxia PT to $9 (Canadian) on Phase 2 EoE trial

General

More